EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Clinical Evidence, Evolving Indications, and Research-Frontier Mapping

Junpeng Luo iD, Xiao Qi, Yandan Wang, Zhimei Huang, Tiandong Chen

Journal of Gastrointestinal Cancer · 28.10.2026 · 57 (1)

DOI: 10.1007/s12029-026-01596-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastrointestinal Cancer, online erschienen am 28.10.2026. Verfasst von Junpeng Luo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medical Center, Huaihe Hospital, Henan University, Kaifeng, Henan, China. hiccp@henu.edu.cn. Hauptthemen laut MEDLINE: Liver Neoplasms, Yttrium Radioisotopes, Carcinoma, Hepatocellular, Radioembolization, Therapeutic. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Key Scientific Research Project of Higher Education Institutions, Henan Provincial Medical Science and Technology Public Relations Program, Provincial Ministerial Co-Construction Key Project, Henan Provincial Medical Science and Technology Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yttrium-90 (Y-90) radioembolization, also termed selective internal radiation therapy (SIRT) or transarterial radioembolization (TARE), is used across the hepatocellular carcinoma (HCC) treatment spectrum as locoregional therapy, bridging or downstaging treatment, radiation segmentectomy, and an emerging partner for systemic therapy. SARAH and SIRveNIB did not show overall survival superiority over sorafenib; DOSISPHERE-01 supported personalized dosimetry; and LEGACY/RASER strengthened radiation segmentectomy in selected solitary HCC. Recent 2025–2026 studies have updated comparative TARE/TACE evidence and combination strategies. We synthesize clinical evidence by indication and integrate a bibliometric analysis of 1,472 high-specificity WoSCC-SCIE records through June 2026 as a triangulation tool, comparing research-frontier signals with unresolved clinical evidence gaps. These signals do not establish efficacy, but they help prioritize trials of Y-90 plus immunotherapy, standardized personalized dosimetry, and contemporary comparisons against TACE or current systemic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsYttrium RadioisotopesCarcinoma, HepatocellularRadioembolization, TherapeuticHumans

Stichwörter der Autor:innen

Hepatocellular carcinomaPersonalized dosimetryRadiation segmentectomySelective internal radiation therapyYttrium-90 radioembolization

Substanzen

Yttrium RadioisotopesYttrium-90

Autor:innen und Institutionen

  • Translational Medical Center, Huaihe Hospital, Henan University, Kaifeng, Henan, China. hiccp@henu.edu.cn.
  • Department of Radiology, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
  • Department of Otolaryngology, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
  • Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Dongfeng East Road 651, Guangzhou, Guangdong Province, 510260, China.
  • Department of Pathology, Henan Cancer Hospital, Zhengzhou, Henan, China.

ORCID-Profile: Junpeng Luo

Förderung

  • Key Scientific Research Project of Higher Education Institutions
  • Henan Provincial Medical Science and Technology Public Relations Program, Provincial Ministerial Co-Construction Key Project
  • Henan Provincial Medical Science and Technology Research Project

Zitieren

APA

Luo, J., Qi, X., Wang, Y., Huang, Z., & Chen, T. (2026). Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Clinical Evidence, Evolving Indications, and Research-Frontier Mapping. Journal of Gastrointestinal Cancer, 57(1). https://doi.org/10.1007/s12029-026-01596-7

Vancouver

Luo J, Qi X, Wang Y, Huang Z, Chen T. Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Clinical Evidence, Evolving Indications, and Research-Frontier Mapping. Journal of Gastrointestinal Cancer. 2026;57(1). doi:10.1007/s12029-026-01596-7

BibTeX
@article{Luo2026,
  author = {Luo, Junpeng and Qi, Xiao and Wang, Yandan and Huang, Zhimei and Chen, Tiandong},
  title = {Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Clinical Evidence, Evolving Indications, and Research-Frontier Mapping},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2026},
  volume = {57},
  number = {1},
  doi = {10.1007/s12029-026-01596-7}
}
Kostenlos starten →